Divis Laboratories has reported results for first quarter ended June 30, 2013.
On standalone basis, the company has posted a rise of 4.38% in its net profit at Rs 174.71 crore for the quarter ended June 30, 2013 as compared to Rs 167.38 crore for the same quarter in the previous year. The total income of the company has increased by 11.84% to Rs 570.57 crore for quarter under review as compared to Rs 510.17 crore for the quarter ended June 30, 2012.
Divis Laboratories, together with its subsidiaries, engaged in the manufacture and sale of active pharma ingredients (APIs) and intermediates for the pharmaceutical industry in India and worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: